AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Feline Calicivirus Vaccine

Technology Benefits

hFCV strains can be used in a new generation of vaccines to produce a much broader spectrum of immunity. More broadly reactive FCV vaccines, immunizing against both common and hemorrhagic strains of vaccine, will provide a new market opportunity.

Technology Application

The FCV vaccine can be used in accordance with routine vaccines as well as in vaccination clinics and veterinarian hospitals in order to fight certain viruses and protect against new as well as old strains.

Detailed Technology Description

Feline calicivirus (FCV) is a common pathogen in multiple cat environments such as shelters and catteries. FCV infection can cause a variety of usually self-limiting signs including fever, upper respiratory signs, acute or chronic oral disease, limping, and occasionally pneumonia. Over the last decade, numerous outbreaks of a highly fatal hemorrhagic form of FCV infection have been observed worldwide. This form of FCV infection often comes from young shelter cats and spreads rapidly by indirect and direct contact to older well-vaccinated household pet cats. Laboratory studies have confirmed these hemorrhagic strains to be resistant to current FCV vaccines. The best way to protect feline populations against this highly fatal form of FCV infection is via vaccines that include a broader immunity. Researchers at the University of California, Davis are proud to offer an invention relating to a vaccine against infections with hemorrhagic feline calicivirus (hFCV). This invention involves the incorporation of particular strains of hFCV into a new generation of vaccines. This invention is available for licensing on a non-exclusive basis.

Supplementary Information

Patent Number: US7309495B2
Application Number: US2003388837A
Inventor: Foley, Janet E. | Hurley, Kate | Pedersen, Niels C.
Priority Date: 14 Mar 2003
Priority Number: US7309495B2
Application Date: 14 Mar 2003
Publication Date: 18 Dec 2007
IPC Current: C12N000700 | A61K0039125 | C07K001408 | C12N000701 | C12N000704 | A61K003900
US Class: 4242161 | 4352351
Assignee Applicant: The Regents of the University of California
Title: Hemorrhagic feline calicivirus
Usefulness: Hemorrhagic feline calicivirus
Summary: The immunogenic composition is useful as a vaccine for immunizing a viral infection caused by a hemorrhagic feline calicivirus (hFCV).
Novelty: New immunogenic composition comprises an amount of a hemorrhagic feline calicivirus (hFCV), useful as a vaccine for immunizing against a hemorrhagic feline calicivirus